These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 16643960)

  • 1. Pre-systemic metabolism prevents in vivo antikinetoplastid activity of N1,N4-substituted 3,5-dinitro sulfanilamide, GB-II-150.
    Wu D; George TG; Hurh E; Werbovetz KA; Dalton JT
    Life Sci; 2006 Aug; 79(11):1081-93. PubMed ID: 16643960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective antimicrotubule activity of N1-phenyl-3,5-dinitro-N4,N4-di-n-propylsulfanilamide (GB-II-5) against kinetoplastid parasites.
    Werbovetz KA; Sackett DL; Delfín D; Bhattacharya G; Salem M; Obrzut T; Rattendi D; Bacchi C
    Mol Pharmacol; 2003 Dec; 64(6):1325-33. PubMed ID: 14645662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and antitubulin activity of N1- and N4-substituted 3,5-dinitro sulfanilamides against African trypanosomes and Leishmania.
    Bhattacharya G; Herman J; Delfín D; Salem MM; Barszcz T; Mollet M; Riccio G; Brun R; Werbovetz KA
    J Med Chem; 2004 Mar; 47(7):1823-32. PubMed ID: 15027874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antikinetoplastid antimitotic activity and metabolic stability of dinitroaniline sulfonamides and benzamides.
    George TG; Johnsamuel J; Delfín DA; Yakovich A; Mukherjee M; Phelps MA; Dalton JT; Sackett DL; Kaiser M; Brun R; Werbovetz KA
    Bioorg Med Chem; 2006 Aug; 14(16):5699-710. PubMed ID: 16675220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, biological evaluation, and molecular modeling of 3,5-substituted-N1-phenyl-N4,N4-di-n-butylsulfanilamides as antikinetoplastid antimicrotubule agents.
    George TG; Endeshaw MM; Morgan RE; Mahasenan KV; Delfín DA; Mukherjee MS; Yakovich AJ; Fotie J; Li C; Werbovetz KA
    Bioorg Med Chem; 2007 Sep; 15(18):6071-9. PubMed ID: 17618122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and metabolism of the prodrug DB289 (2,5-bis[4-(N-methoxyamidino)phenyl]furan monomaleate) in rat and monkey and its conversion to the antiprotozoal/antifungal drug DB75 (2,5-bis(4-guanylphenyl)furan dihydrochloride).
    Midgley I; Fitzpatrick K; Taylor LM; Houchen TL; Henderson SJ; Wright SJ; Cybulski ZR; John BA; McBurney A; Boykin DW; Trendler KL
    Drug Metab Dispos; 2007 Jun; 35(6):955-67. PubMed ID: 17360833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo metabolism and final disposition of a novel nonsteroidal androgen in rats and dogs.
    Perera MA; Yin D; Wu D; Chan KK; Miller DD; Dalton J
    Drug Metab Dispos; 2006 Oct; 34(10):1713-21. PubMed ID: 16815963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and antikinetoplastid activity of a series of N,N'-substituted diamines.
    Caminos AP; Panozzo-Zenere EA; Wilkinson SR; Tekwani BL; Labadie GR
    Bioorg Med Chem Lett; 2012 Feb; 22(4):1712-5. PubMed ID: 22248858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of enhanced bioavailability and diuretic effect of azosemide by ascorbic acid in rats.
    Choi KY; Kim YC; Lee MG
    Life Sci; 2006 Feb; 78(10):1057-62. PubMed ID: 16153662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and antiprotozoal activity of cationic 2-phenylbenzofurans.
    Bakunov SA; Bakunova SM; Wenzler T; Barszcz T; Werbovetz KA; Brun R; Tidwell RR
    J Med Chem; 2008 Nov; 51(21):6927-44. PubMed ID: 18841956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and antiprotozoal activity of pyridyl analogues of pentamidine.
    Bakunova SM; Bakunov SA; Wenzler T; Barszcz T; Werbovetz KA; Brun R; Tidwell RR
    J Med Chem; 2009 Aug; 52(15):4657-67. PubMed ID: 19606902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biopharmaceutical characterization of 450191-S, a ring-opened derivative of 1,4-benzodiazepine. II. Evidence for reduced first-pass extraction by rat liver.
    Koike M; Futaguchi S; Takahashi S; Sugeno K
    Drug Metab Dispos; 1988; 16(4):609-15. PubMed ID: 2903031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs.
    Beconi MG; Reed JR; Teffera Y; Xia YQ; Kochansky CJ; Liu DQ; Xu S; Elmore CS; Ciccotto S; Hora DF; Stearns RA; Vincent SH
    Drug Metab Dispos; 2007 Apr; 35(4):525-32. PubMed ID: 17220241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereoselective first-pass metabolism of verapamil in the small intestine and liver in rats.
    Hanada K; Ikemi Y; Kukita K; Mihara K; Ogata H
    Drug Metab Dispos; 2008 Oct; 36(10):2037-42. PubMed ID: 18617604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sex differences in the pharmacokinetics, oxidative metabolism and oral bioavailability of oxycodone in the Sprague-Dawley rat.
    Chan S; Edwards SR; Wyse BD; Smith MT
    Clin Exp Pharmacol Physiol; 2008 Mar; 35(3):295-302. PubMed ID: 17973932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and first-pass effects of liquiritigenin in rats: low bioavailability is primarily due to extensive gastrointestinal first-pass effect.
    Kang HE; Cho YK; Jung HY; Choi KY; Sohn SI; Baek SR; Lee MG
    Xenobiotica; 2009 Jun; 39(6):465-75. PubMed ID: 19480552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Redox-active dinitrodiphenylthioethers against Leishmania: synthesis, structure-activity relationships and mechanism of action studies.
    Delfín DA; Morgan RE; Zhu X; Werbovetz KA
    Bioorg Med Chem; 2009 Jan; 17(2):820-9. PubMed ID: 19058972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and antiprotozoal activities of dicationic bis(phenoxymethyl)benzenes, bis(phenoxymethyl)naphthalenes, and bis(benzyloxy)naphthalenes.
    Patrick DA; Bakunov SA; Bakunova SM; Kumar EV; Chen H; Jones SK; Wenzler T; Barzcz T; Werbovetz KA; Brun R; Tidwell RR
    Eur J Med Chem; 2009 Sep; 44(9):3543-51. PubMed ID: 19409677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolism and pharmacokinetics of a novel Src kinase inhibitor TG100435 ([7-(2,6-dichloro-phenyl)-5-methyl-benzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine) and its active N-oxide metabolite TG100855 ([7-(2,6-dichloro-phenyl)-5-methylbenzo[1,2,4]triazin-3-yl]-{4-[2-(1-oxy-pyrrolidin-1-yl)-ethoxy]-phenyl}-amine).
    Hu SX; Soll R; Yee S; Lohse DL; Kousba A; Zeng B; Yu X; McPherson A; Renick J; Cao J; Tabak A; Hood J; Doukas J; Noronha G; Martin M
    Drug Metab Dispos; 2007 Jun; 35(6):929-36. PubMed ID: 17371799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.